The PI3K-NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis

Arthritis Research and Therapy

Volumn 8, Issue 1, 2006, Pages

  Fishman, Pnina ^a,b   Bar Yehuda, Sara ^a,b   Madi, Lea ^a   Rath Wolfson, Lea ^b   Ochaion, Avivit ^a   Cohen, Shira ^a   Baharav, Ehud ^b  

^a Can Fite BioPharma Ltd   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A3 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N(6)-(3-IODOBENZYL)-5'-N-METHYLCARBOXAMIDOADENOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; SIGNAL PEPTIDE;

ANALOGS AND DERIVATIVES; ANIMAL; ARTHRITIS, EXPERIMENTAL; FEMALE; LEWIS RAT; LYMPH NODE; METABOLISM; MONOCYTE; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SYNOVIUM;

ADENOSINE; ADENOSINE A3 RECEPTOR ANTAGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; FEMALE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; MONOCYTES; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE;

EID: 70449564383     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1887     Document Type: Article

References (39)

1. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76:5-13.
2. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S: Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 1997, 45 132-139.
3. Mabley J, Soriano F, Pacher P, Hasko G, Marton A, Wallace R, Salzman A, Szabo C: The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 2003, 466 323-329.
4. Fishman P, Bar-Yehuda S: Pharmacology and therapeutic applications of A3 receptor subtype. Curr Top Med Chem 2003, 3:463-469.
5. Pouliot M, Fiset ME, Massé M, Naccache PH, Borgeat P: Adenosine up-regulates cyclooxygenase-2 in human granulocytes: Impact on the balance of eicosanoid generation. J Immunol 2002, 169 5279-5286.
6. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES: Adenosine receptor agonists differentially regulate IL-10, TNFalpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice J Immunol 1996, 157:4634-4640.
7. Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK, Seok JH, Lee JH, Hur GM: Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 2000, 47:35-44.
8. Cronstein BN, Montesinos MC, Weissmann G: Sites of action for future therapy: An adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NFkappaB knockout mice Osteoarthritis Cartilage 1999, 7:361-363.
9. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN: Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000, 43:656-663.
10. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, Buckley MT, Carlin G, Cronstein BN: The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996, 156:1937-1941.
11. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Hasko G: Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists Br J Pharmacol 1998, 125:379-387.
12. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P: The antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005, 32:469-476.
13. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, Cronstein BN: Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003, 48:240-247.
14. Schutle G, Fredholm BB: Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 2002, 62(5):1137-1146.
15. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K: Evidence for involvement of Wnt signaling pathway in IBMECA mediated suppression of melanoma cells. Oncogene 2002, 21:4060-4064.
16. Ohana G, Bar-Yehuda S, Arich A, Madi L, Dreznick Z, Rath-Wolfson L, Silberman D, Slosman G, Fishman P: Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist IB-MECA. Br J Cancer 2003, 89:1552-1558.
17. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, Fishman P: A3 adenosine receptor activation in melanoma cells: Association between receptor fate and tumor growth inhibition. J Biol Chem 2003, 278:42121-42130.
18. Hanada T, Yoshimura A: Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002, 13:413-421.
19. Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S: Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages. Mol Pharmacol 1997, 52:421-429.
20. Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL, Boyle DL, Manning AM, Firestein GS: Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001, 44:1897-1907.
21. Liu H, Pope RM: The role of apoptosis in rheumatoid arthritis. Curr Opin Pharmacol 2003, 3:317-322.
22. Baraldi PG, Cacciari B, Pineda de Las Infantas MJ, Romagnoli R, Spalluto G, Volpini R, Costanzi S, Vittori S, Cristalli G, Melman N, et al. Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5′-N-ethyluronamide as A1 and A3 adenosine receptor agonists. J Med Chem 1998, 41:3174-3185.
23. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
24. van Troostenburg AR, Clark EV, Carey WDH, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KLL, Fishman P: Tolerability, pharmacokinetics, and concentrationdependent hemodynamic effects of oral IB-MECA, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004, 42:534-542.
25. Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, Ochaion A, Madi L: Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 2003, 23:2077-2083.
26. Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger A, Madi L: An agonist to the A(3) adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3beta and NF-kappaB. Oncogene 2004, 23(14):2465-2471.
27. McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, De M, Borcherding DR, Edwards CK 3rd: Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol 1996, 310:209-216.
28. Krasilnikov MA: Phosphatidylinositol-3 kinasT dependent pathways: the role in control of cell growth, survival, and malignant transformation Biochemistry (Mosc) 2000, 65:59-67.
29. Wang K, Scheel-Toellner D, Wong SH, Craddock R, Caamano J, Akbar AN, Salmon M, Lord JM: Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signaling pathways. J Immunol 2003, 171:1035-1041.
30. Pap T, Muller-Ladner U, Gay RE, Gay S: Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000, 2361-367.
31. Yang KY, Arcaroli J, Kupfner J, Pitts TM, Park JS, Strasshiem D, Perng RP, Abraham E: Involvement of phosphatidylinositol 3-kinase gamma in neutrophil apoptosis. Cell Signal 2003, 15:225-233.
32. Stoica BA, Movsesyan VA, Lea PM, Faden AI: Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 2003, 22:365-382.
33. Miyashita T, Kawakami A, Tamai M, Izumi Y, Mingguo H, Tanaka F, Abiru S, Nakashima K, Iwanaga N, Aratake K, et al.: Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem Biophys Res Commun 2003, 312:397-404.
34. Gessi S, Cattabriga E, Avitabile A, Gafa' R, Lanza G, Cavazzini L, Bianchi N, Gambari R, Feo C, Liboni A, et al.: Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 2004, 10:5895-5901.
35. Xaus J, Mirabet M, Lloberas J, Soler C, Lluis C, Franco R, Celada A: IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: A mechanism of macrophage deactivation. J Immunol 1999, 162:3607-3614.
36. Capecchi PL, Camurri A, Pompella G, Mazzola A, Maccherini M, Diciolla F, Lazzerini PE, Abbracchio MP, Laghi-Pasini F: Upregulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation. J Card Fail 2005, 11:67-73.
37. Zhang HG, Wang Y, Xie JF, Liang X, Liu D, Yang P, Hsu HC, Ray RB, Mountz JD: Regulation of tumor necrosis factor alphamediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum 2001, 44:1555-1567.
38. Capone ML, Tacconelli S, Sciulli MG, Patrignani P: Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003, 16:49-58.
39. Burke JR: Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr Opin Drug Discov Devel 2003, 6(5):720-728.